HHS Secretary Robert F. Kennedy Jr. announced new federal actions targeting Lyme disease and other tick-borne illnesses, backed by AI-powered diagnostic tools and a personal appeal from actor Dennis Quaid.
Kennedy laid out the initiative in a video posted to his official X account on Monday, framing the effort as long overdue for the nearly half a million Americans diagnosed and treated for Lyme disease every year. Quaid appeared alongside him as a patient advocate, recounting the misdiagnosis that cost his late friend, singer and actor Kris Kristofferson, years of proper treatment.
The announcement builds on a slate of Lyme-focused initiatives Kennedy first rolled out in May at the New Hampshire State House. That earlier package included a multimillion-dollar CDC tick-control pilot, up to $2.5 million in LymeX innovation challenges, a public-private clinician-locator partnership, and a stated goal: cut Lyme disease cases 25 percent by 2035, measured against 2022 levels.
Monday's update centered on concrete tools. Kennedy said HHS is investing millions in AI-powered technology designed to improve care, speed diagnosis, and accelerate research into tick-borne illness. He pointed to two improved Lyme diagnostics that have now received FDA clearance, developed through HHS's partnership with the LymeX community.
Kennedy described the stakes plainly:
"Millions of Americans need faster diagnoses, better care, and real answers."
He expanded on the diagnostic push in the video:
"HHS has worked with the LymeX community to help bring two improved FDA-cleared Lyme diagnostics to market, giving clinicians better tools and helping more patients get an accurate diagnosis sooner."
Kennedy also urged patients to submit their treatment histories through Cure ID, a free app co-managed by the FDA and the National Institutes of Health. The app collects real-world treatment data, the kind of ground-level information that federal health agencies have historically been slow to gather. Patients looking for experienced doctors can now search by zip code through a clinician locator at hhs.gov/lyme.
Quaid's presence gave the announcement a human dimension that policy rollouts rarely carry. He told the story of Kristofferson, the country music icon and actor who spent years under an Alzheimer's diagnosis before doctors identified the real culprit.
"But Alzheimer's wasn't the problem. He actually had Lyme disease and when the doctors finally diagnosed him correctly in 2016 and started the right treatment, his symptoms did improve."
Kristofferson's case is a sharp illustration of the diagnostic failure Kennedy is targeting. A man with one of the most recognizable names in American entertainment spent years being treated for the wrong disease. If the medical system failed him, ordinary patients without his resources face far worse odds.
The Washington Examiner has reported that between 10 and 20 percent of treated Lyme patients remain symptomatic for years, a population that the medical establishment has often struggled to help and sometimes dismissed outright.
The scale of the problem dwarfs what most Americans assume. HHS figures Kennedy cited at his May announcement put the number of annual Lyme diagnoses at more than 476,000. That is not a niche concern. It is a public health burden larger than many conditions that receive far more federal attention and research funding.
Lyme disease is not the only target. Monday's announcement also addressed alpha-gal syndrome, a tick-triggered condition that causes allergic reactions to red meat and other mammal-derived products, and other tick-borne illnesses that have expanded their geographic reach in recent years. Kennedy mentioned the broader category in his announcement but did not detail specific new actions for alpha-gal beyond the umbrella initiative.
Kennedy has folded the Lyme campaign into his "Take Back Your Health" tour and the broader Make America Healthy Again agenda. The MAHA framework has drawn skepticism from parts of the public health establishment, but the Lyme initiative is harder to dismiss. Faster diagnostics, better clinician access, and real-world treatment data are practical steps, not ideological gestures.
The May package at the New Hampshire State House set the foundation. LymeX innovation challenges, funded at up to $2.5 million, were designed to draw private-sector talent into a space that government agencies had largely neglected. The CDC tick-control pilot, described as multimillion-dollar, addressed prevention on the ground level. And the clinician-locator partnership tackled a basic problem: patients in many parts of the country cannot find a doctor who knows how to treat tick-borne illness competently.
Monday's additions, the AI-powered tools, the two new FDA-cleared diagnostics, and the Cure ID data push, move the effort from planning into deployment. Kennedy's HHS is betting that technology can close a diagnostic gap that has persisted for decades, one that has left patients bouncing between specialists and spending years searching for answers.
For the millions of Americans living in tick-heavy regions, the federal government's track record on Lyme disease has been one of institutional indifference. Kennedy is staking his credibility on changing that. If HHS delivers on the 25 percent reduction target by 2035, it will be one of the most measurable public health wins any cabinet secretary has claimed in years.
Washington has spent decades telling sick Americans to wait for better science. Kennedy is telling them to submit their own data, find a real doctor, and demand a correct diagnosis. That alone is a departure worth watching.
